178 related articles for article (PubMed ID: 24666307)
1. Recent advances in structure of progestins and their binding to progesterone receptors.
Cabeza M; Heuze Y; Sánchez A; Garrido M; Bratoeff E
J Enzyme Inhib Med Chem; 2015 Feb; 30(1):152-9. PubMed ID: 24666307
[TBL] [Abstract][Full Text] [Related]
2. Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins.
Petit-Topin I; Turque N; Fagart J; Fay M; Ulmann A; Gainer E; Rafestin-Oblin ME
Mol Pharmacol; 2009 Jun; 75(6):1317-24. PubMed ID: 19289570
[TBL] [Abstract][Full Text] [Related]
3. Targeting progesterone receptors in breast cancer.
Giulianelli S; Molinolo A; Lanari C
Vitam Horm; 2013; 93():161-84. PubMed ID: 23810006
[TBL] [Abstract][Full Text] [Related]
4. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity.
Attardi BJ; Hild SA; Reel JR
Endocrinology; 2006 Jun; 147(6):3016-26. PubMed ID: 16497801
[TBL] [Abstract][Full Text] [Related]
5. Contraceptive progestins. Various 11-substituents combined with four 17-substituents: 17alpha-ethynyl, five- and six-membered spiromethylene ethers or six-membered spiromethylene lactones.
Schoonen WG; Deckers G; de Gooijer ME; de Ries R; Mathijssen-Mommers G; Hamersma H; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2000 Oct; 74(3):109-23. PubMed ID: 11086230
[TBL] [Abstract][Full Text] [Related]
6. Endocrinological properties of two novel nonsteroidal progesterone receptor modulators, CP8816 and CP8863.
Kurata Y; Tabata Y; Shinei R; Iizuka Y; Masuda NT; Kurihara K; Okonogi T; Hoshiko S
J Pharmacol Exp Ther; 2005 May; 313(2):916-20. PubMed ID: 15743919
[TBL] [Abstract][Full Text] [Related]
7. A new strategy for selective targeting of progesterone receptor with passive antagonists.
Khan JA; Tikad A; Fay M; Hamze A; Fagart J; Chabbert-Buffet N; Meduri G; Amazit L; Brion JD; Alami M; Lombès M; Loosfelt H; Rafestin-Oblin ME
Mol Endocrinol; 2013 Jun; 27(6):909-24. PubMed ID: 23579486
[TBL] [Abstract][Full Text] [Related]
8. Progestins induce catalase activities in breast cancer cells through PRB isoform: correlation with cell growth inhibition.
Petit E; Courtin A; Kloosterboer HJ; Rostène W; Forgez P; Gompel A
J Steroid Biochem Mol Biol; 2009 Jul; 115(3-5):153-60. PubMed ID: 19383545
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal progesterone receptor modulators: structure activity relationships.
Winneker RC; Fensome A; Wrobel JE; Zhang Z; Zhang P
Semin Reprod Med; 2005 Feb; 23(1):46-57. PubMed ID: 15714389
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 7α-methyl-19-nortestosterone effectiveness alone or combined with progestins on androgen receptor mediated-transactivation.
García-Becerra R; Ordaz-Rosado D; Noé G; Chávez B; Cooney AJ; Larrea F
Reproduction; 2012 Feb; 143(2):211-9. PubMed ID: 22065861
[TBL] [Abstract][Full Text] [Related]
11. [Cytotoxic activity and molecular modeling of progestins - pregna-D'-pentarans].
Scherbakov AM; Levina IS; Kulikova LE; Fedyushkina IV; Skvortsov VS; Veselovsky AV; Kuznetsov YV; Zavarzin IV
Biomed Khim; 2016 Mar; 62(3):290-4. PubMed ID: 27420621
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay.
McRobb L; Handelsman DJ; Kazlauskas R; Wilkinson S; McLeod MD; Heather AK
J Steroid Biochem Mol Biol; 2008 May; 110(1-2):39-47. PubMed ID: 18395441
[TBL] [Abstract][Full Text] [Related]
13. Nortestosterone-derived synthetic progestogens do not activate the progestogen receptor of Murray-Darling rainbowfish (Melanotaenia fluviatilis) but are potent agonists of androgen receptors alpha and beta.
Bain PA; Kumar A; Ogino Y; Iguchi T
Aquat Toxicol; 2015 Jun; 163():97-101. PubMed ID: 25863598
[TBL] [Abstract][Full Text] [Related]
14. The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells.
Horwitz KB
Endocrinology; 1985 Jun; 116(6):2236-45. PubMed ID: 4039656
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.
Bray JD; Jelinsky S; Ghatge R; Bray JA; Tunkey C; Saraf K; Jacobsen BM; Richer JK; Brown EL; Winneker RC; Horwitz KB; Lyttle CR
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):328-41. PubMed ID: 16157482
[TBL] [Abstract][Full Text] [Related]
16. An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity.
Wei LL; Hawkins P; Baker C; Norris B; Sheridan PL; Quinn PG
Mol Endocrinol; 1996 Nov; 10(11):1379-87. PubMed ID: 8923464
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
18. Contraceptives with novel benefits.
Su Y; Lian QQ; Ge RS
Expert Opin Investig Drugs; 2012 Jan; 21(1):83-90. PubMed ID: 22149760
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of partially fluorinated antiprogestins and mesoprogestins.
Nickisch K; Elger W; Cessac J; Kesavaram N; Das B; Garfield R; Shi SQ; Amelkina O; Meister R
Steroids; 2013 Feb; 78(2):255-67. PubMed ID: 23178161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
